JP7764471B2 - 腎機能の低下抑制又は改善用組成物 - Google Patents

腎機能の低下抑制又は改善用組成物

Info

Publication number
JP7764471B2
JP7764471B2 JP2023517170A JP2023517170A JP7764471B2 JP 7764471 B2 JP7764471 B2 JP 7764471B2 JP 2023517170 A JP2023517170 A JP 2023517170A JP 2023517170 A JP2023517170 A JP 2023517170A JP 7764471 B2 JP7764471 B2 JP 7764471B2
Authority
JP
Japan
Prior art keywords
composition
ergothioneine
renal function
salt
decline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023517170A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022230491A1 (https=
Inventor
諒 勝部
斉志 渡辺
宣人 村山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of JPWO2022230491A1 publication Critical patent/JPWO2022230491A1/ja
Application granted granted Critical
Publication of JP7764471B2 publication Critical patent/JP7764471B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023517170A 2021-04-26 2022-03-25 腎機能の低下抑制又は改善用組成物 Active JP7764471B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021074321 2021-04-26
JP2021074321 2021-04-26
PCT/JP2022/014246 WO2022230491A1 (ja) 2021-04-26 2022-03-25 腎機能の低下抑制又は改善用組成物

Publications (2)

Publication Number Publication Date
JPWO2022230491A1 JPWO2022230491A1 (https=) 2022-11-03
JP7764471B2 true JP7764471B2 (ja) 2025-11-05

Family

ID=83847930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517170A Active JP7764471B2 (ja) 2021-04-26 2022-03-25 腎機能の低下抑制又は改善用組成物

Country Status (7)

Country Link
US (1) US20240173298A1 (https=)
EP (1) EP4331581A4 (https=)
JP (1) JP7764471B2 (https=)
CN (1) CN117241796A (https=)
AU (1) AU2022267110A1 (https=)
TW (1) TW202308613A (https=)
WO (1) WO2022230491A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230000829A1 (en) * 2019-10-28 2023-01-05 Suntory Holdings Limited Composition for sleep improvement comprising ergothioneine or salt thereof
CN121001582A (zh) * 2023-03-28 2025-11-21 三得利控股株式会社 含有麦角硫因或其盐的用于预防、减轻或改善中暑或脱水症的组合物及用于调节细胞内外水分的组合物
CN120241721A (zh) * 2025-04-25 2025-07-04 武汉大学中南医院 麦角硫因在制备肾损伤保护药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021018774A1 (en) 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
JP5658479B2 (ja) 2009-04-27 2015-01-28 株式会社岩出菌学研究所 脂肪減少等の活性を示す組成物
US20120141611A1 (en) * 2010-12-05 2012-06-07 Oxis International Inc. Methods and compositions using ergothioneine to treat a variety of health related factors
US20140121156A1 (en) * 2011-06-13 2014-05-01 Entia Biosciences, Inc. Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine
CA3122246C (en) * 2018-12-05 2025-06-10 Celagenex Research (India) Pvt. Ltd. Synergistic compositions of bioactive agents to optimize cell health
CN113308378B (zh) * 2020-02-26 2022-11-29 华南农业大学 高产麦角硫因的灵芝菌株及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021018774A1 (en) 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof

Also Published As

Publication number Publication date
TW202308613A (zh) 2023-03-01
WO2022230491A1 (ja) 2022-11-03
EP4331581A4 (en) 2025-04-09
AU2022267110A1 (en) 2023-10-05
JPWO2022230491A1 (https=) 2022-11-03
US20240173298A1 (en) 2024-05-30
EP4331581A1 (en) 2024-03-06
CN117241796A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
JP7764471B2 (ja) 腎機能の低下抑制又は改善用組成物
US20240180876A1 (en) Composition for increasing red blood cells and/or hemoglobin
JP7796116B2 (ja) 抗不安用組成物
JP7796118B2 (ja) 白血球及び／又は好塩基球増加用組成物
JP7796117B2 (ja) 血中コレステロール値改善用組成物
US20240189284A1 (en) Composition for promoting lipolysis
CN118251219A (zh) 组胺n-甲基转移酶阻碍用组合物
HK40103317A (zh) 肾功能的降低抑制或改善用组合物
WO2024172002A1 (ja) エルゴチオネインを含有する血管拡張用組成物
WO2024203675A1 (ja) エルゴチオネイン又はその塩を含有する熱中症又は脱水症を予防、軽減又は改善するための組成物及び細胞内外水分を調節するための組成物
HK40104490A (zh) 脂肪分解促进用组合物
HK40103316A (zh) 红血球及/或血红蛋白增加用组合物
HK40103319A (zh) 血中胆固醇值改善用组合物
WO2024172003A1 (ja) エルゴチオネインを含有する筋萎縮抑制用組成物及びＳｒｃチロシンキナーゼ阻害用組成物
AU2023318410A1 (en) Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material
AU2022417968A1 (en) Oral composition and method for suppressing bitterness derived from ergothioneine
HK40113453A (zh) 口服组合物以及抑制来自麦角硫因的苦味的方法
HK40111999A (zh) 组胺n-甲基转移酶阻碍用组合物
HK40075030A (en) Composition for sleep improvement comprising ergothioneine or salt thereof
TW202342005A (zh) 經口組成物，及，抑制源自麥角硫因或其鹽之苦味及源自二十碳五烯酸類之臭味之方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251023

R150 Certificate of patent or registration of utility model

Ref document number: 7764471

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150